Next Article in Journal
Recrystallization of Commercial Carbamazepine Samples—A Strategy to Control Dissolution Variability
Next Article in Special Issue
Probiotic Encapsulation Technology: From Microencapsulation to Release into the Gut
Previous Article in Journal
Tissue Engineered Human Skin Equivalents
Previous Article in Special Issue
Trojan Microparticles for Drug Delivery
Pharmaceutics 2012, 4(1), 42-57; doi:10.3390/pharmaceutics4010042

Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles

1,* , 3
Received: 1 December 2011 / Revised: 31 December 2011 / Accepted: 31 December 2011 / Published: 11 January 2012
(This article belongs to the Special Issue Microencapsulation Technology Applied to Pharmaceutics)
View Full-Text   |   Download PDF [759 KB, uploaded 11 January 2012]   |   Browse Figures


Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (0.5–3 µm in diameter). LMW-H/P MPs immobilize, control the release and protect the activity of GFs. LMW-H/P MPs can also bind to cell surfaces, causing these cells to interact with the LMW-H/P MPs, inducing cells/MPs-aggregate formation and substantially promoting cellular viability. Furthermore, LMW-H/P MPs can efficiently bind to tissue culture plates and retain the binding of important GFs, such as fibroblast growth factor (FGF)-2. The LMW-H/P MPs-coated matrix with various GFs or cytokines may provide novel biomaterials that can control cellular activity such as growth and differentiation. Thus, LMW-H/P MPs are an excellent carrier for GFs and various cells and are an efficient coating matrix for cell cultures.
Keywords: entrapment; microparticles; coating; polymeric drug delivery systems entrapment; microparticles; coating; polymeric drug delivery systems
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Kishimoto, S.; Ishihara, M.; Takikawa, M.; Mori, Y.; Hattori, H.; Fujita, M.; Nakamura, S. Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles. Pharmaceutics 2012, 4, 42-57.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert